Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies


Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1136/ard.2008.094359

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Antibodies, Monoclonal /therapeutic use; Antirheumatic Agents /therapeutic use; Arthritis, Rheumatoid /drug therapy /economics; Drug Costs; Female; Follow-Up Studies; Guideline Adherence; Health Care Costs; Humans; Male; Middle Aged; Monte Carlo Method; Patient Compliance; Patient Selection; Practice Guidelines as Topic; Probability; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alpha /antagonists & inhibitors

AccessionNumber
22009102189

Date bibliographic record published
05/08/2009